This retrospective, observational study compared clinical outcomes of adults with T2D switching from Gla-100/IDet to Gla-300 or IDeg. Electronic medical records (Predictive Health Intelligence Environment database) (3/1/15-1/31/17) were analyzed. Switchers with ≥1 A1C during 6—month baseline were propensity score matched on baseline demographic and clinical characteristics (including percentage of patients originally on Gla-100/IDet). Endpoints were A1C change and goal attainment in those with ≥1 A1C test during 3-6-month follow-up, and hypoglycemia (hypo) in all 3184 matched patients. Hypo (ICD-9/ 10 and/or plasma-glucose level ≤70 mg/dL overall, or associated with an inpatient/ED encounter) was assessed using fixed follow-up (intent-to-treat [ITT], full 6 months) and variable follow-up (on treatment [OT], till discontinuation or 6 months). A1C reduction was comparable between Gla-300 (n=742) and IDeg (n=727) switchers (0.63% and 0.58%, respectively, p=0.49). A1C <7% was attained in 15.1%/16.1% among Gla-300/IDeg switchers, respectively (p=0.63); <8% in 44.3%/44.4%, respectively (p=0.98). By ITT, switching to Gla-300 (n=1592) reduced hypo incidence (all: 15.6% to 12.7%; p=0.01; inpatient/ED: 5.3% to 3.5%; p=0.01); switching to IDeg (n=1592) resulted in non-significant reductions (all: 14.3% to 12.7%; p=0.12; inpatient/ED: 4.1% to 3.6%; p=0.40). After adjusting baseline hypo incidence, no significant differences were found in follow-up between the two groups. By OT, hypo incidence was similar in both groups (adjusted hazard ratio: 1.02; p=0.88), but Gla-300 switchers had lower inpatient/ED hypo event rates in follow-up (adjusted rate ratio: 0.56; p=0.02). In a real-world setting of adults with T2D, switching from Gla-100/IDet to Gla—300 or IDeg resulted in comparable improvements in glycemic control and comparable/better hypo outcomes.


S.D. Sullivan: None. T.S. Bailey: Research Support; Self; Abbott. Consultant; Self; Abbott. Speaker's Bureau; Self; Abbott. Research Support; Self; Ambra BioScience, Ascensia Diabetes Care, Becton, Dickinson and Company. Consultant; Self; Becton, Dickinson and Company. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Calibra Medical. Consultant; Self; Calibra Medical. Research Support; Self; Companion Medical, Dexcom, Inc., Glooko, Inc., GlySens Incorporated, Lexicon Pharmaceuticals, Inc., Eli Lilly and Company. Consultant; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Research Support; Self; Medtronic MiniMed, Inc.. Consultant; Self; Medtronic MiniMed, Inc.. Speaker's Bureau; Self; Medtronic MiniMed, Inc.. Research Support; Self; Novo Nordisk Inc.. Consultant; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Research Support; Self; Sanofi. Consultant; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Research Support; Self; Senseonics. Consultant; Self; Intarcia Therapeutics, Inc.. Research Support; Self; Versartis, Inc., Xeris Pharmaceuticals, Inc., MannKind Corporation. R. Roussel: Advisory Panel; Self; AbbVie Inc., Abbott, Eli Lilly and Company, Sanofi, Novo Nordisk A/S, AstraZeneca. Speaker's Bureau; Self; Servier. Consultant; Self; Bayer AG. Advisory Panel; Self; Merck Sharp & Dohme Corp.. Research Support; Self; Amgen Inc., Sanofi, Novo Nordisk A/S, Danone Research. Stock/Shareholder; Self; Iriade. Advisory Panel; Self; Physiogenex S.A.S. F.L. Zhou: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. Employee; Spouse/Partner; Lexicon Pharmaceuticals, Inc.. Stock/Shareholder; Spouse/Partner; Lexicon Pharmaceuticals, Inc. Z. Bosnyak: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. R. Preblick: Employee; Self; Sanofi. J. Westerbacka: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. R. Gupta: Other Relationship; Self; Sanofi. L. Blonde: Other Relationship; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca. Advisory Panel; Self; Intarcia Therapeutics, Inc.. Other Relationship; Self; Lexicon Pharmaceuticals, Inc.. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Other Relationship; Self; Janssen Scientific Affairs, LLC.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Merck & Co., Inc., Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Other Relationship; Self; Novo Nordisk Inc., Sanofi. Advisory Panel; Self; Sanofi. Speaker's Bureau; Self; Sanofi US.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at